AlphAIAlphAI — Financial news for AI agents
tradingview.comOCT 221 min read$KPTI

KPTI Q3'26 Earnings: revenue estimate is 33.54M USD

Karyopharm Therapeutics (KPTI) will report Q3'26 earnings on October 29. Analysts expect $33.54M revenue and $(0.95) EPS. Details available on the company's financials page.

Original reporting
tradingview.com
Published Oct 22, 2026, 11:01 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 22, 2026, 11:09 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
KPTI Q3'26 Earnings: revenue estimate is 33.54M USD — source image
Source · tradingview.com
Decision brief

The 30-second read

$KPTINeutralLow
01

Why it matters

The earnings preview provides the first public revenue estimate for Q3'26, setting expectations for investors.

02

Market read

The article introduces new earnings guidance for KPTI, offering traders a basis for positioning ahead of the Oct 29 release.

03

What to watch

Potential upcoming clinical trial data or partnership announcements not mentioned in the preview.

Relevance 5/10Novelty 4/10Timing: pre‑market on Oct 29

Background

Karyopharm Therapeutics is a clinical‑stage biotech focused on nuclear transport inhibitors.

Company-level read

Ticker impact

$KPTINeutralMedium confidence
Context

Karyopharm Therapeutics (KPTI) will release its Q3'26 earnings on Oct 29 with revenue estimated at $33.54M and EPS of -$0.95.

Expected impact

likely pressure as the market prices in the low revenue guidance

Evidence & confidence

Guidance is below expectations for a growth biotech, so investors may react negatively if results align with the estimate.

Market effects

Sector

Biotech earnings season may see broader sector pressure if KPTI's guidance signals slower growth.

Regional

U.S. biotech investors may adjust exposure ahead of the release.

Global

Limited; impact confined to biotech and related ETFs.

Counterpoint

What could challenge this read

If the company beats the low guidance, the stock could rally sharply on surprise upside.

Key entities

  • company
    Karyopharm Therapeutics Inc.

    Biotech firm reporting Q3'26 earnings.

Read at source← All news

Related articles

NOV 2
$KPTIHighAI 8/10

A cancer drug company filed for bankruptcy protection. Its merger plan could face competing bids.

Karyopharm Therapeutics filed for Chapter 11 bankruptcy protection, aiming to maximize value through a court-supervised sale process. Ayrmid will serve as the lead bidder, with a focus on advancing therapies for multiple myeloma and myelofibrosis. Karyopharm secured commitments for financing and plans to continue operations without disruption. Parties interested in bidding can contact Centerview Partners.

stocktitan.net2 min
AUG 21
$KPTIHighAI 8/10

Karyopharm’s (KPTI) Big Cancer Bet Faces A Ticking Clock

Karyopharm Therapeutics (KPTI) reported Q2 earnings, highlighting a potential FDA accelerated approval for its myelofibrosis combination therapy, while also facing a cash crunch with funds lasting only until September. The company's selinexor and ruxolitinib combination showed promising results, but a $15.8 million loan payment due soon could trigger a default if not addressed. Karyopharm is exploring financing options and strategic alternatives.

insidermonkey.com3 min
AUG 20
$KPTIMed

Karyopharm (KPTI) Q2 2026 Earnings Call Transcript

Karyopharm (KPTI) reported Q2 2026 revenue of $33.4M, down from $37.9M YoY due to expired agreements. U.S. XPOVIO revenue rose to $30.8M. Net loss was $67M, including non-cash expenses. The company faces a $15.8M debt payment in September, risking a liquidity covenant breach. Management reaffirmed full-year revenue guidance of $130M-$150M and plans to submit an sNDA for selinexor in myelofibrosis.

fool.com2 min